Interpace Biosciences® is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer.
Interpace Biosciences is a fully integrated commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. Through our subsidiary, Interpace Diagnostics® LLC, we develop and commercialize molecular diagnostic tests that deliver cutting-edge genetic and mutational analysis. Our tests help risk-stratify patient samples for thyroid, pancreatic, lung, and other cancers to better inform treatment decisions.
Interpace Diagnostics currently has four commercialized molecular tests; PancraGEN®, an integrated molecular pathology platform used for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts and lesions; ThyGeNEXT®, a Next Generation Sequencing based mutation profile that identifies mutations from thyroid nodules that are highly indicative of thyroid cancer when traditional cytology is indeterminate; ThyraMIR®, a proprietary, microRNA based classifier that works with ThyGeNEXT to assist physicians in identifying those thyroid nodules least likely to be malignant when traditional cytology is indeterminate; and RespriDx®, used for distinguishing lesions in the lung that represent new tumors from those caused by metastases from other organs. The Company also has a development portfolio that includes BarreGEN® for Barrett’s Esophagus, a test that enables physicians to identify those patients with this common diagnosis that are most likely to progress to esophageal cancer so intervention can be performed.
Interpace Diagnostics was formed in April, 2014 as a Division of PDI, Inc., (created in 1998 as a public company with over 1,000 employees that provided Contract Sales services to pharmaceutical companies.) After the sale of the pharmaceutical contract sales business in December of 2015, Interpace Diagnostics Group became the sole operating company and the name PDI was changed to Interpace Diagnostics Group, Inc. In July of 2019, the Company acquired the biopharma services division of Cancer Genetics, Inc., renaming this acquisition Interpace Pharma Solutions and changing the holding company name to Interpace Biosciences. Interpace Pharma Solutions was sold to Flagship Biosciences in August, 2022. The public company status remains the same (OTCQX: IDXG). Interpace Biosciences is an independent molecular diagnostics company that provides services to specialty physicians and medical centers throughout the U.S. and internationally.